Effective Management of Polycythemia Vera With Ropeginterferon Alfa-2b Treatment.

Background: Polycythemia vera (PV) is a myeloproliferative neoplasm. Ropeginterferon alfa-2b is a new-generation polyethylene glycol-conjugated proline-interferon. It is approved for the treatment of PV at a starting dose of 100 µg (50 µg for patients receiving hydroxyurea (HU)) and dose titrations up to 500 µg by 50 µg increments.

[Clinical Analysis of Hospitalized Children with Primary Immune Thrombocytopenia].

Objective: To investigate the factors affecting the chronicity of childhood primary immune thrombo-cytopenia (ITP) and compare the efficiency of different first-line treatment regimens.

Methods: Children with ITP hospitalized in our hospital from September 2013 to October 2018 were retrospectively analyzed.

Results: Three hundred and one children (150 males and 151 females) were included in this study, with a median age of 8 (0.

[Symptomatic Profiles of 173 Chinese Patients with Essential Thrombocythemia].

Objective: To explore the symptomatic burden of patients with essential thrombocythemia (ET) and its relation with clinical characteristics including the mutation status, therapeutic protocols and sex.

Methods: Total of 173 Chinese ET patients were selected and grouped on the basis of disease characteristics (mutation status, therapeutic pro to- cols, and sex).

Results: All the groups showed low-to-high symptom burden, with the highest in the Hu (hydroxyurea)-group (total symptom score [TSS], 14.

[Clinical Characteristic of "triple-negative" Essential Thrombocythaemia Patients and Mutation Analysis by Targeted Sequencing].

Background: Essential thrombocythemia is a subgroup of myeloproliferative neoplasms. Previous studies identified mutations of JAK2, CALR, and MPL that are closely related with the pathogenesis of myeloproliferative neoplasms. All these mutations contribute to the hyperactivation of JAK2/STAT pathway.

[Clinical Characteristics and Long-Term Outcome of 125 Chinese Young Patients with Essential Thrombocythemia].

Objective: To investigate the clinical characteristics and long-term outcome of Chinese young patients (≤40 years) with essential thrombocythemia(ET), and to develop a thrombosis predicting model specific for young patients with ET, so as to provide a new evidence for risk stratification and treatment.

Methods: Medical records of 125 Chinese young patients with newly diagnosed of ET were retrospectively analyzed.

Results: The median age at diagnosis was 32 (18-40) years old, with 37 males and 88 females.

[Role of Toll-like receptor 2 in primary immune thrombocytopenia].

The aim of this study was to explore the role of Toll-like receptor (TLR) 2 in primary immune thrombocytopenia (ITP) by detecting TLR2 expression in the peripheral blood lymphocytes of patients with ITP and evaluating the role of TLR2 activation on inflammatory cytokine secretion. A total of 39 ITP patients and 21 normal controls were enrolled in this study. The expression of TLR2 was detected by real-time PCR and flow cytometry, and the concentration of IL-6 and TNF-α in culture supernatant of PBMNC treated with pam3CSK4 for 48 hours were detected by ELISA.

[Clinical characteristics of 520 children with hemophilia in a single medical center].

Objective: To analyze the clinical characteristics, diagnosis and treatment of pediatric hemophilia in single center over the decade.

Methods: A retrospective study was conducted with 520 hemophilic children hospitalized in our medical center between January 2002 and December 2012.

Results: All the patients were male including 438 hemophilia A (HA) and 82 hemophilia B (HB).